Abstract
Mitochondrial cardiomyopathy (MCM) is characterized by abnormal heart-muscle structure and function, caused by mutations in the nuclear genome or mitochondrial DNA. The heterogeneity of gene mutations and various clinical presentations in patients with cardiomyopathy make its diagnosis, molecular mechanism, and therapeutics great challenges. This review describes the molecular epidemiology of MCM and its clinical features, reviews the promising diagnostic tests applied for mitochondrial diseases and cardiomyopathies, and details the animal and cellular models used for modeling cardiomyopathy and to investigate disease pathogenesis in a controlled in vitro environment. It also discusses the emerging therapeutics tested in pre-clinical and clinical studies of cardiac regeneration.
Funder
Start-up Grant for Stem Cell Regenerative Medicine
Shenzhen Science and Technology Program
Reference99 articles.
1. Mitochondrial cardiomyopathies;El-Hattab;Front. Cardiovasc. Med.,2016
2. Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies;Ramachandra;Cardiovasc. Res.,2021
3. Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases;Limongelli;Future Cardiol.,2012
4. Mitochondrial cardiomyopathy: Pathophysiology, diagnosis, and management;Meyers;Texas Heart Inst. J.,2013
5. Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases;Stojkovic;Future Cardiol.,2015
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献